iWOnDer: Role of Natural Light in the Prevention of Delirium After Cardiac Surgery: a Prospective Observational Study With Historical Control

Sponsor
Azienda Ospedaliero-Universitaria di Parma (Other)
Overall Status
Recruiting
CT.gov ID
NCT05936944
Collaborator
(none)
300
1
15.6
19.2

Study Details

Study Description

Brief Summary

Postoperative delirium is a common complication that usually occurs acutely within the first 24 hours after surgery and resolves within 72 hours; it is common in all medical areas and particularly affects patients over the age of 65 and those with pre-existing cognitive impairments. It is characterized by difficulty organizing and coordinating thoughts and by slowing down motor functions that are observed for a short period after surgery.

The study will be an observational prospective study with historical control (pre/post-study) whose primary objective is to identify the incidence of postoperative delirium in patients undergoing cardiac surgery. The population will be adult patients undergoing cardiac surgery at our University Hospital over a period of 12 months. The intervention will be exposure to totally artificial light (for patients hospitalized after the relocation of the department to its original location). The comparator will be exposure to natural light (for patients who will be hospitalized during our temporary transfer to an environment with natural lighting). The outcome will be the incidence of delirium, measured with the Confusion Assessment Method-Intensive Care Unit (CAM-ICU) scale; episodes of agitation requiring sedative drugs; time elapsed before onset of delirium. The study will last 12 months.

Condition or Disease Intervention/Treatment Phase
  • Other: Exposure to totally artificial lighting

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Ruolo Della Luce Naturale Nella Prevenzione Del Delirium Dopo Cardiochirurgia: Studio Osservazionale Prospettico Con Controllo Storico
Actual Study Start Date :
Jun 14, 2023
Anticipated Primary Completion Date :
Jun 14, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Natural Light

Group of patients enrolled in the first ICU, with natural lighting

Artificial Light

Group of patients enrolled in the second ICU, with totally artificial lighting

Other: Exposure to totally artificial lighting
The second group of patients will be admitted to an ICU without windows and with a totally artificial lighting

Outcome Measures

Primary Outcome Measures

  1. Postoperative delirium [first five postoperative days or ICU discharge (wichever comes first)]

    Occurrence of delirium, diagnosed with at least one positive CAM-ICU evaluation

Secondary Outcome Measures

  1. Postoperative episodes of agitation [first five postoperative days or ICU discharge (wichever comes first)]

    number of episodes of postoperative agitation (RASS>+1) requiring farmacological treatment

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • planned cardiac surgery

  • planned ICU admission after surgery

Exclusion Criteria:
  • cardiac surgery with total suspension of cerebral perfusion

  • patient with diagnosed dementia or major depressive disorder

  • patient unable to perform CAM-ICU evaluation

  • emergent surgery

  • patient in ICU before surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ospedale Maggiore di Parma Parma PR Italy 43126

Sponsors and Collaborators

  • Azienda Ospedaliero-Universitaria di Parma

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Davide Nicolotti, MD, Azienda Ospedaliero-Universitaria di Parma
ClinicalTrials.gov Identifier:
NCT05936944
Other Study ID Numbers:
  • SIRER 6097
First Posted:
Jul 10, 2023
Last Update Posted:
Jul 10, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Davide Nicolotti, MD, Azienda Ospedaliero-Universitaria di Parma
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 10, 2023